ArticleMedical & biological engineering & computing2022
Automated method for real-time AMD screening of fundus images dedicated for mobile devices.
Article in Medical & biological engineering & computing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 18 citations in OpenAlex.
- Knowledge, attitudes, and practices of patients with age-related macular degeneration (AMD) towards Anti-VEGF treatment under one-stop intravitreal injection model.Scientific reports · 2024Article
- Clinical Applications and Future Directions of Smartphone Fundus Imaging.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Aged macular degeneration (AMD) leads to a progressive decline in visual acuity until reaching blindness. It is considered as an irreversible pathology where an early diagnosis remains crucial. However, the lack of ophthalmologists, the permanent increase in elderly people, and their limited mobility involves a delay in AMD diagnosis. In this paper, we propose an automated method for AMD screening. The proposed processing pipeline consists in applying the well-known Radon transform to the macula region in order to model the AMD lesions even with a moderate quality of smartphone-captured fundus images. Thereby, the relevant features are carefully selected, related to the main proprieties of drusens, and then provided to an SVM classifier. The implementation of the method into a smartphone associated to a fundus image capturing device leads to a mobile CAD system that performs higher performance AMD screening. Within this framework and to achieve a real-time implementation, an optimization approach is suggested in order to reduce the processing workload. The evaluation of our method is carried out through the three public STARE, REFUGE, and RFMiD databases. A 4-fold cross-validation approach is used to evaluate the method performance where accuracies of 100%, 95.2%, and 94.3% are respectively obtained with STARE, REFUGE, and RFMiD databases. Comparisons with the state-of-the-art methods in the literature are done. Thereafter, the robustness of the proposed method was evaluated and proved. We note that 100% accuracy was preserved despite the use of degraded quality fundus images as noisy and blurred. Moreover, the propounded method was implemented in S7-Edge and S9 Smartphone devices, where the execution times of 19 and 15 milliseconds were respectively achieved, which proves the AMD real-time detection. Taking advantage of its mobility, cost-effective, detection performance, and reduced execution time, our proposed method seems a good solution for real-time AMD screening on mobile devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.